Search
brentuximab vedotin/doxorubicin/vinblastine/dacarbazine (A+AVD)
Indications:
- antineoplastic combination for treatment of Hodgkin's disease
* superior to ABVD in patients with advanced Hodgkin's disease [1]
Related
Hodgkin's disease (Hodgkin's lymphoma)
General
antineoplastic combination (combination chemotherapy)
References
- Connors JM, Jurczak W, Straus DJ et al
Brentuximab Vedotin with Chemotherapy for Stage III or IV
Hodgkin's Lymphoma.
N Engl J Med. Dec 10, 2017
PMID: 29224502
http://www.nejm.org/doi/full/10.1056/NEJMoa1708984
- Longo DL, DeVita DT Jr.
Progress in the Treatment of Hodgkin's Lymphoma.
N Engl J Med. Dec 10, 2017
PMID: 29224505
http://www.nejm.org/doi/full/10.1056/NEJMe1715141
Components
brentuximab vedotin (Adcetris)
dacarbazine (DTIC)
doxorubicin (Adriamycin, Rubex)
vinblastine; vincaleukoblastine (Velban, Velsar, Alkaban-AQ)